Cargando…

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer

BACKGROUND: Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear. METHODS: We developed an open-source TMEscore R package, to quantify the tumor microenvironme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Dongqiang, Wu, Jiani, Luo, Huiyan, Li, Yong, Xiao, Jian, Peng, Jianjun, Ye, Zilan, Zhou, Rui, Yu, Yunfang, Wang, Gaofeng, Huang, Na, Wu, Jianhua, Rong, Xiaoxiang, Sun, Li, Sun, Huiying, Qiu, Wenjun, Xue, Yichen, Bin, Jianping, Liao, Yulin, Li, Nailin, Shi, Min, Kim, Kyoung-Mee, Liao, Wangjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356190/ https://www.ncbi.nlm.nih.gov/pubmed/34376552 http://dx.doi.org/10.1136/jitc-2021-002467

Ejemplares similares

Immunosuppressive Microenvironment Revealed by Immune Cell Landscape in Pre-metastatic Liver of Colorectal Cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
por: Lv, Kunpeng, et al.
Publicado: (2023)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma
por: Zeng, Liang, et al.
Publicado: (2023)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
por: Chen, Xisha, et al.
Publicado: (2022)

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study
por: Zhao, Jianli, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
por: Filipski, Katharina, et al.
Publicado: (2021)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
por: Zhou, Jian-Guo, et al.
Publicado: (2021)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers
por: Ying, Jieer, et al.
Publicado: (2021)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qikl3mr597hd8gce9s5rnr74et